CliffBio
biologic

Xolair

omalizumab

Loss of exclusivityAugust 2035projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameXolair
Active ingredientomalizumab
Strength75MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2023
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.